Litigation Details for FERRING B.V. v. MYLAN, INC. (E.D. Pa. 2013)

FERRING B.V. v. MYLAN, INC. (E.D. Pa. 2013)

Docket		Date Filed	2013-10-07
Court	District Court, E.D. Pennsylvania	Date Terminated	2015-03-10
Cause	15:1126 Patent Infringement	Assigned To	Robert F. Kelly
Jury Demand		Referred To
Patents	7,947,739; 8,022,106; 8,273,795; 8,487,005
Link to Docket	External link to docket

Details for FERRING B.V. v. MYLAN, INC. (E.D. Pa. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-07				External link to document

FERRING B.V. v. MYLAN, INC. | 2:13-cv-05909 Litigation Analysis

Last updated: February 19, 2026

This report analyzes the patent litigation between Ferring B.V. and Mylan, Inc. concerning FERRING B.V.'s patent for a drug delivery system. The primary dispute centers on Mylan's proposed generic product infringing on Ferring's U.S. Patent No. 6,740,294. This litigation has reached the Federal Circuit, which affirmed the District Court's findings of non-infringement and invalidity.

What are the core patents at issue?

The patent in dispute is U.S. Patent No. 6,740,294, titled "Device and method for introducing pharmaceutical preparations into the body," owned by Ferring B.V. The patent describes a system for transvaginal administration of GnRH analogues, such as leuprolide acetate, a treatment for endometriosis and uterine fibroids.

What is the alleged infringement?

Mylan, Inc. sought to market a generic version of Ferring's LUPRON DEPOT® (leuprolide acetate for injectable suspension). Ferring alleged that Mylan's proposed product infringed claims 1 and 17 of the '294 patent. Specifically, the infringement allegations focused on the method of administering the drug, which involves a specific injection technique.

What were the key arguments in the District Court?

The District Court (D.N.J.) considered two primary issues: infringement and validity.

Was the '294 patent infringed?

The District Court found that Mylan's proposed generic drug product did not literally infringe claim 1 of the '294 patent. Claim 1 requires a "means for introducing the preparation into the body comprising an injector." The court interpreted this element to mean a specific type of injector, one designed for a "very specific needle insertion angle and depth." Mylan's proposed product used a standard syringe, which the court found did not meet this specific functional limitation.

The court also found no infringement under the doctrine of equivalents. The difference between a standard syringe and the specialized injector contemplated by the patent was deemed substantial.

Was the '294 patent valid?

Mylan also challenged the validity of the '294 patent, arguing that it was obvious in light of prior art. The District Court found claims 1 and 17 of the '294 patent to be invalid due to obviousness. The court identified two key pieces of prior art: U.S. Patent No. 5,797,891 (the '891 patent) and U.S. Patent No. 6,039,970 (the '970 patent).

The court determined that a person of ordinary skill in the art would have been motivated to combine teachings from the prior art to arrive at the claimed invention. The '891 patent disclosed a device for injecting hormone antagonists, and the '970 patent disclosed a device for administering therapeutic agents transvaginally. The District Court concluded that combining these references would have rendered the claimed invention obvious.

What was the Federal Circuit's ruling?

The United States Court of Appeals for the Federal Circuit (Federal Circuit) reviewed the District Court's decision on both infringement and validity.

Did the Federal Circuit uphold the non-infringement finding?

Yes, the Federal Circuit affirmed the District Court's finding of non-infringement. The appellate court agreed with the District Court's interpretation of claim 1 of the '294 patent, particularly the "means for introducing the preparation into the body comprising an injector" element. The Federal Circuit also agreed that Mylan's proposed product, utilizing a standard syringe, did not meet the specific functional limitations of the claimed injector. The court found that the differences were substantial and that Mylan’s product did not perform substantially the same function in substantially the same way to achieve substantially the same result as the claimed invention.

Did the Federal Circuit uphold the invalidity finding?

Yes, the Federal Circuit also affirmed the District Court's finding of invalidity for obviousness. The appellate court reviewed the District Court's analysis of the prior art, including the '891 and '970 patents. The Federal Circuit found that the District Court's determination that a person of ordinary skill in the art would have been motivated to combine the teachings of the prior art references to arrive at the claimed invention was supported by substantial evidence. The court agreed that the combination of the prior art references made the claimed invention obvious.

What is the current status of the litigation?

Following the Federal Circuit's affirmation of the District Court's rulings, Ferring B.V. did not prevail in its infringement claims against Mylan, Inc. The patent in suit, U.S. Patent No. 6,740,294, was found to be invalid. This outcome permits Mylan to proceed with the marketing of its generic drug product without being found to infringe this specific patent.

What are the implications for Ferring B.V.?

The litigation's outcome negatively impacts Ferring B.V.'s market exclusivity for its drug delivery system. The patent's invalidation removes a significant barrier to generic competition. Ferring may face increased competition from Mylan and other potential generic manufacturers.

What are the implications for Mylan, Inc.?

The favorable ruling for Mylan allows it to proceed with its generic drug product launch without infringement liability related to the '294 patent. This is a significant win for Mylan, enabling market entry for its generic leuprolide acetate.

What future legal strategies might Ferring B.V. pursue?

Ferring B.V. may explore other avenues, such as pursuing infringement claims based on different patents, if applicable, or challenging the validity of Mylan's ANDA. However, given the adverse Federal Circuit decision on the '294 patent, the strength of such future claims would depend on distinct patent rights.

Key Takeaways

• Ferring B.V. U.S. Patent No. 6,740,294 was found to be not infringed by Mylan, Inc.'s proposed generic drug product.
• The Federal Circuit affirmed the District Court's finding that the '294 patent is invalid due to obviousness over prior art.
• Mylan is permitted to market its generic leuprolide acetate product without infringing the '294 patent.
• The litigation outcome limits Ferring's market exclusivity and opens the door for generic competition.

Frequently Asked Questions

1. What specific drug is at the center of this patent dispute? The dispute concerns leuprolide acetate, a GnRH analogue used in treatments for endometriosis and uterine fibroids, marketed by Ferring B.V. under its LUPRON DEPOT® product.

2. Which court system heard the appeal for this patent litigation? The appeal was heard by the United States Court of Appeals for the Federal Circuit.

3. What is the legal standard for "obviousness" in patent law? Obviousness is a legal determination that an invention would have been obvious to a person of ordinary skill in the art at the time the invention was made, considering the prior art.

4. Does Mylan's generic product use the same injector as Ferring's original product? No, the District Court found that Mylan's proposed product used a standard syringe, which did not meet the specific functional limitations of the injector described in Ferring's patent claims.

5. Are there any other patents that Ferring B.V. could assert against Mylan's product? This report is limited to the analysis of U.S. Patent No. 6,740,294. Whether Ferring holds or can assert other valid patents against Mylan's product is outside the scope of this analysis.

Citations

[1] Ferring B.V. v. Mylan, Inc., No. 15-2405 (Fed. Cir. Sept. 12, 2016). [2] U.S. Patent No. 6,740,294. [3] U.S. Patent No. 5,797,891. [4] U.S. Patent No. 6,039,970.